Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 16, 2009

View Archived Issues

Novel Hsp90 inhibitors under development at Merck KGaA for the treatment of cancer

Merck & Co. imparts novel HDAC inhibitors for treating cancer

Torrent claims novel Hsp70 inducers with potential for treating stroke

Novel deuterated oseltamivir analogues developed at Protia for influenza

Recent Dainippon Sumitomo patent reports new renin inhibitors with antihypertensive properties

Protia imparts novel deuterated tenofovir analogues with anti-HIV properties

NeoPharm submits application to FDA for phase II study of LE-DT in prostate cancer

Astex and Cancer Research U.K. sign CTA for AT-9283 in childhood cancer

Dainippon Sumitomo recaps Q3 developments

Novogen plans to focus activities on its oncology program

No serious adverse events seen with OBP-601 in phase I study

NeuroSearch discontinues ABT-894 program in diabetic neuropathic pain

Oasmia's phase III Paclical study generates physician interest in Europe

Octapharma commences phase II study of Octagam in Alzheimer's disease

Oral laquinimod granted FDA fast track designation for multiple sclerosis

Conditionally replicative adenovirus shows activity in phase I ovarian cancer trial

Roche signs nonexclusive license agreement with MDRNA for RNAi-based therapeutics

HIV-1 subtype A/E vaccine is safe but not highly immunogenic in healthy Thai subjects

Telik implements reorganization to focus on Telintra and leading preclinical candidates

CD4 T cells modified ex vivo by lentiviral vector traffic to lymphoid tissues in HIV patients

Antisense presents update on development

IDMC for phase III trial of motesanib recommends resumption of enrollment

Doctors can now predict Pegasys treatment success in hepatitis B patients

France approves named patient supply for Ark's Cerepro

Teijin and Takeda receive FDA approval for febuxostat for hyperuricemia in gout

ViroPharma discontinues maribavir phase III liver transplant study

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 27, 2026.
Detecting the invisible: minimal residual disease at AACR 2026
BioWorld Science
Minimal residual disease (MRD) has become a central concept in modern oncology, reshaping how clinicians evaluate response, relapse risk and treatment precision....
A free gene therapy? Regeneron’s Otarmeni approved for hearing loss
BioWorld
Children and adults with a type of congenital hearing loss now have a free treatment option, with the U.S. FDA’s accelerated approval of Regeneron Pharmaceuticals...
AACR 2026: The age of agentic AI in oncology
BioWorld Science
New Approach Methodologies (NAMs) for drug development are transforming biomedical research by replacing or complementing animal models. More than 90% of...
Chengdu Mfs Pharma synthesizes new compounds for pain
BioWorld Science
Chengdu Mfs Pharma Co. Ltd. has prepared and tested compounds for the potential treatment of pain, sleep disorder and status epilepticus epilepsy as well as for...